Eylea 40 mg/mL solution for injection in a vial
VGFTe-ROP-2036
Phase 3 small_molecule active
Quick answer
Eylea 40 mg/mL solution for injection in a vial for Retinopathy of prematurity (ROP) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Retinopathy of prematurity (ROP)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active